Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) EBITDA
Johnson & Johnson's EBITDA for fiscal 2025 was $42.1B, up 61.3% from $26.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $34.9B. Over the past ten years it has ranged from $23.6B (fiscal 2015) to $42.1B (fiscal 2025) — the current reading is the highest in ten years. Johnson & Johnson ranks 2nd of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $42.1B | 61.26% |
| FY2024 | $26.1B | 6.23% |
| FY2023 | $24.6B | (9.28%) |
| FY2022 | $27.1B | 1.09% |
| FY2021 | $26.8B | 11.50% |
| FY2020 | $24.0B | (3.89%) |
| FY2019 | $25.0B | (5.77%) |
| FY2018 | $26.5B | 7.75% |
| FY2017 | $24.6B | (0.07%) |
| FY2016 | $24.7B | 4.36% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $9.2B | 8.37% |
| Mar 2026 | $8.5B | 14.36% |
| Dec 2025 | $7.4B | (23.75%) |
| Sep 2025 | $9.7B | 8.22% |
| 42 more quarters | Free account |
Against its own ten years
Low $23.6B
High $42.1B
Ten-year median
$25.0B
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| LLY Eli Lilly and Company compare | $35.7B |
| JNJ Johnson & Johnson | $34.9B |
| ABBV AbbVie Inc. compare | $25.6B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. compare | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. compare | $16.5B |
| MRK Merck & Co., Inc. compare | $13.7B |
| GILD Gilead Sciences, Inc. compare | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on JNJ
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement